Kishan Mehta - 01 Dec 2025 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Reporting relationship: Director
Issuer ticker: BNTC
Reported as of: 01 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Dec 2025, 16:19:44 UTC
Prior SEC filing: 07 May 2025
Next SEC filing: 19 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Kishan Mehta

Key filing fact

Kishan Mehta filed Form 4 for Benitec Biopharma Inc. (BNTC) on 03 Dec 2025.

Key facts

This page summarizes Kishan Mehta's Form 4 filing for Benitec Biopharma Inc. (BNTC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Dec 2025, 16:19.

Change

Previous filing in this sequence was filed on 07 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001850520 Primary reporting owner

Mehta Kishan

Relationship: Director
Address: C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD
Signature: /s/ Kishan Mehta
Signature date: 03 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BNTC transaction Derivative

Options (right to buy)

Award

Transaction value: $0
Shares: +35,000
Change %
Price: $0.000000
Shares after: 35,000
Date: 01 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $12.23
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.

Footnote F2

The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.